Back to News
Market Impact: 0.25
Vir Biotechnology Partners With Gilead On Next-Generation Cancer Immunotherapy Programs
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
Vir Biotechnology entered a multi-program collaboration and license agreement with Gilead Sciences to discover and develop three PRO-XTEN dual-masked T-cell engager candidates targeting selected solid tumors. The article excerpt provides no financial terms or development milestones.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
GILD0.35
VIR0.45
More News
- Why is Samsung Electronics stock plunging today?
- SK Hynix plunges 8% amid Asia tech rout as Fed rate hike fears, AI funding worries mount
- Elon Musk says Trump is 'ultimately' responsible for any curbs on Ukraine's Starshield systems
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Rocket Lab stock tumbling today?